Paragon Sports Medicine

Home/ Peptides/ Hexarelin

BAck to all peptides

Hexarelin

Hexarelin is a synthetic hexapeptide belonging to the growth hormone secretagogue (GHS) family, specifically designed to stimulate endogenous growth hormone (GH) release through selective activation of growth hormone secretagogue receptors (GHS-R). Originally developed as a potent secretagogue, hexarelin represents a targeted approach to growth hormone optimization that works by enhancing the body's natural GH production rather than providing exogenous hormone replacement.

This peptide has gained considerable attention in endocrinology and sports medicine for its studied role in promoting lean muscle mass development, enhancing fat metabolism, improving cardiovascular function, and providing anti-inflammatory benefits. Hexarelin exhibits unique receptor specificity and maintains bioactivity across various physiological conditions, making it distinctive among growth hormone secretagogues with applications in metabolic health and performance optimization.

Molecular structure diagram of Hexarelin peptide showing carbon, nitrogen, oxygen atoms, and peptide bonds.

Overview

Hexarelin's structure incorporates several non-natural amino acids, including D-2-methyl-tryptophan and D-phenylalanine, which enhance resistance to enzymatic degradation and improve pharmacokinetic properties. The peptide is metabolized primarily in the liver with renal elimination, and demonstrates detectability up to 8 hours post-administration using specialized analytical methods.

Patient consulting with Dr. Ched Garten at Paragon, symbolizing advanced non-surgical care for joint, tendon, muscle, and pain issues.

Chemical structure & Properties

  • Molecular Formula: C47H58N12O6
  • Molecular Weight: 887.03 Da
  • Sequence: His-D-2-Methyl-Trp-Ala-Trp-D-Phe-Lys-NH2
  • Half-life: Approximately 1-2 hours following subcutaneous administration
  • Stability: Stable peptide requiring refrigerated storage when reconstituted

Mechanism of Action

Hexarelin exerts its therapeutic effects through multiple interconnected molecular pathways:

Growth Hormone Secretagogue Receptor (GHS-R) Activation

Hexarelin activates growth hormone release pathways, leading to:

  • High-affinity binding to GHS-R (ghrelin receptors) in hypothalamus and pituitary
  • Activation of G-protein coupled signaling pathways
  • Stimulation of intracellular calcium mobilization and cAMP elevation
  • Enhancement of pulsatile growth hormone release patterns

Growth Hormone and IGF-1 Axis Stimulation

The peptide promotes endogenous hormone production through:

  • Significant elevation of growth hormone levels (up to 4-fold increase from baseline)
  • Secondary stimulation of insulin-like growth factor-1 (IGF-1) production
  • Enhancement of growth hormone binding protein expression
  • Optimization of GH/IGF-1 axis function and downstream anabolic signaling

Metabolic Regulation

Hexarelin influences metabolism by:

  • Enhanced lipolysis and fatty acid oxidation in adipose tissue
  • Increased muscle protein synthesis and lean mass development
  • Improved glucose metabolism and insulin sensitivity
  • Modulation of leptin and adiponectin expression for metabolic optimization

Anti-inflammatory Effects

The peptide demonstrates anti-inflammatory properties through:

  • Reduction of pro-inflammatory cytokines (IL-6, TNF-α)
  • Enhancement of anti-inflammatory mediator expression
  • Protection against oxidative stress and cellular damage
  • Promotion of tissue repair and regenerative processes

Areas Investigated in

the Research Literature

Endocrine Applications

Growth Hormone Deficiency: Clinical studies demonstrate hexarelin's efficacy in treating:

  • Age-related GH decline with restoration to youthful levels
  • Adult growth hormone deficiency as alternative to replacement therapy
  • Metabolic dysfunction associated with GH insufficiency
  • Preservation of natural pulsatile hormone release patterns

Mechanism: Hexarelin stimulates the hypothalamic-pituitary axis to restore physiological GH production, addressing underlying deficiency rather than providing exogenous hormone replacement.

Body Composition: Research indicates potential benefits in:

  • Significant increases in lean muscle mass through enhanced protein synthesis
  • Facilitation of lipolysis and reduction in body fat percentage
  • Prevention of age-related sarcopenia and muscle wasting
  • Enhanced physical performance and functional capacity

Cardiovascular Applications

Cardiac Function Enhancement: Hexarelin demonstrates protective effects against:

  • Heart failure and cardiac dysfunction
  • Age-related cardiovascular decline
  • Ischemia-reperfusion injury
  • Impaired cardiac contractility

Mechanism: Direct cardioprotective effects through GH-independent cardiac effects are linked to CD36 signaling in cardiac tissue, providing unique therapeutic advantages.

Anti-inflammatory Applications

Tissue Protection: Preclinical evidence supports potential benefits in:

  • Acute lung injury with improved lung compliance
  • Systemic inflammatory conditions
  • Protection against tissue damage in various organ systems
  • Enhanced tissue repair and regenerative processes

Mechanism: Comprehensive anti-inflammatory effects through cytokine modulation, oxidative stress reduction, and tissue-protective signaling pathways.

Patient consulting with Dr. Ched Garten at Paragon, symbolizing advanced non-surgical care for joint, tendon, muscle, and pain issues.

Current Clinical Evidence

Safety Profile and Considerations

Clinical Safety Data

Research across multiple studies demonstrates:

  • Allergic-type reactions have been reported, including hives, throat tightness, and rare progression toward shortness of breath; monitor carefully.
  • Safety data limited to small studies; not established in large human trials
  • With continuous daily use, growth hormone response can fade as the system adapts.
  • Hexarelin can acutely raise cortisol, ACTH, and prolactin; monitor endocrine effects.

Potential Concerns

Growth Factor Stimulation Risk:

  • Theoretical concern regarding growth factor stimulation in malignancy
  • No direct evidence of cancer promotion in current studies
  • Caution advised in patients with active malignancy or cancer history

Drug Interactions:

  • Potential metabolic effects requiring glucose monitoring in diabetic patients
  • Limited data on interactions with other medications
  • Enhanced monitoring recommended for cardiovascular conditions

Contraindications

Hexarelin should be avoided in:

  • Active malignancy (theoretical concern regarding growth factor stimulation)
  • Known hypersensitivity to hexarelin or related peptides
  • Pregnancy and breastfeeding (insufficient safety data)
  • Severe cardiac arrhythmias (requires cardiac monitoring)

Regulatory Status and Legal Considerations

Regulatory information current as of 28 August 2026. This is a summary, not legal or medical advice, and status can change.

FDA Status

  • Classification: Research peptide, not approved for therapeutic use
  • Approval Status: Not approved for human therapeutic use
  • Development Stage: Preclinical and early clinical development
  • Regulatory Position: Limited human studies completed, larger trials needed

WADA Status

  • Classification: S2 growth hormone secretagogue; prohibited at all times.
  • Athletic Use: Banned in competitive sports
  • Testing: Detectable in anti-doping screenings

Legal Availability

  • Commercial Status: Not legally available as prescription medication
  • Market Presence: Available through research institutions and specialized suppliers
  • Quality Control: Significant variability in commercial preparations
  • Clinical Use: Limited to research settings and experimental protocols
Man seated indoors with a soccer ball in natural light, representing Paragon’s musculoskeletal recovery expertise and regenerative treatment focus.

Conclusion

What the evidence supports

Hexarelin is a growth-hormone secretagogue that has been studied in animal models and small human studies for effects on growth hormone release, body composition and cardiac tissue. Human data is limited and short-term, dosing has not been standardized, and there is no long-term safety record. Hexarelin is not FDA approved for any therapeutic use and is prohibited under WADA. This page summarizes the published research and nothing further.

HEXARELIN SCIENTIFIC

DATA SUMMARY

MOLECULAR CHARACTERISTICS
PRECLINICAL EFFICACY DATA
CLINICAL EVIDENCE SUMMARY
SAFETY PROFILE
REGULATORY STATUS
Parameter
Molecular Weight
Amino Acid Length
Half-Life
Bioavailability
Detection Window
Value
887.03 Da
6 residues
1-2 hours (hepatic)
High via subcutaneous (>80%)
8 hours
Application
Growth Hormone Release
Cardiovascular Function
Anti-inflammatory
Body Composition
Reported outcome (model)
4-fold GH increase, peak 10.2 ng/mL
Increased cardiac output and ejection fraction in animal models
Reduced IL-6 and TNF-α
No significant change in total body fat, lean body mass, or bone mineral density.
Study Type
GH Response Study
Cardiovascular Study
Pulmonary Study
Population
Elderly subjects (Rahim)
Cardiac models (Mao)
Lung injury models (Zambelli)
Results
Significant GH elevation
Improved cardiac parameters
Reduced inflammation
Limitations
Body composition dependent
Predominantly preclinical data
Clinical translation required
Parameter
Acute Toxicity
Organ Toxicity
Adverse Events
Long-term Safety
Finding
Serious adverse events have been reported during clinical development; available safety data should be interpreted cautiously.
Hexarelin can acutely raise cortisol, ACTH, and prolactin; monitor endocrine effects.
Mild injection site reactions (5-10%)
Limited long-term data; GH response attenuates with continuous use
Authority
FDA
WADA
DEA
Classification
Research Peptide
S2 growth hormone secretagogue
Unscheduled
Status
Not approved for human use
Prohibited at all times.
Not controlled substance

About this library

This library is published for education. It summarizes published research on compounds studied in this field. Many have no approved medical use, and several cannot lawfully be compounded in the United States. The presence of a page here does not mean Paragon offers that compound. Nothing on these pages is an offer to treat.

This page is general education about a compound studied in this field. Nothing here is medical advice, a recommendation, or an offer to prescribe or supply. A page appearing in this library does not mean Paragon Sports Medicine offers that compound.

Disclaimer: This information is provided for educational purposes only and does not constitute medical advice. Hexarelin is not approved by the FDA for human therapeutic use and is prohibited by WADA for athletic use. Patients should consult with qualified healthcare providers before considering any peptide therapy.

Statements on this page have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Many peptides described here are not FDA approved for the uses discussed, and some cannot lawfully be compounded in the United States. Nothing on this page is medical advice or a recommendation for any individual. Whether any therapy is appropriate depends on your history, your laboratory results, and a clinical evaluation. Individual results vary. This page is published for education. Use of this site does not create a physician-patient relationship.

References

01
The cardiovascular action of hexarelin. J Geriatr Cardiol. 2014.
02
CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res. 2002.
03
Implications of ghrelin and hexarelin in diabetes and diabetes-associated heart diseases. Endocrine. 2015.
04
Hexarelin attenuates abdominal aortic aneurysm formation by inhibiting SMC phenotype switch and inflammasome activation. Microvasc Res. 2022.
05
Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway. Eur J Med Res. 2023.